By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video

Key Statistics

Ownership: Public

Web Site: Actavis
Symbol: ACT


Company News
Actavis (ACT) Registration Statement For Pending Acquisition Of Allergan (AGN) Declared Effective By The SEC 1/27/2015 7:46:01 AM
Actavis (ACT)' Buying Spree Continues With $460 Million Deal 1/26/2015 6:06:07 AM
Actavis (ACT), Aurobindo Pharma (AUROBINDOP.BO) Recall Thousands of Neurontin Bottles 1/21/2015 7:11:42 AM
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015 6:00:44 AM
Actavis (ACT) Launches U.S. Generic Specialty Injectable Portfolio 1/13/2015 9:36:25 AM
Actavis (ACT) And Allergan (AGN) Announce Early Termination Of Hart-Scott-Rodino Waiting Period For Actavis' Pending Acquisition Of Allergan And Record Dates For Shareholder Meetings 1/12/2015 10:04:48 AM
Actavis (ACT) Announces Exceptional Preliminary Fourth Quarter 2014 Performance 1/12/2015 9:11:44 AM
Adamas Pharmaceuticals (ADMS) Receives $30 Million Milestone Payment From Actavis (ACT) 1/9/2015 7:23:19 AM
Actavis (ACT) Confirms Appeals Court Grants Expedited Appeal Of Ruling Requiring Continued Distribution Of NAMENDA® IR 1/6/2015 2:11:29 PM
Actavis (ACT) And Gedeon Richter Ltd. (RIG2.F) Announce FDA Receipt Of NDA Resubmission For Cariprazine 1/6/2015 7:24:27 AM